ArticleHypertension research : official journal of the Japanese Society of Hypertension2026
Independent and joint associations of fatty liver index and physical activity with mortality in adults with hypertension: a nationwide cohort study.
Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension and non-alcoholic fatty liver disease (NAFLD) frequently coexist and share metabolic pathways that elevate cardiovascular and all-cause mortality risk. Although physical activity (PA) is known to reduce cardiovascular risk, its impact among individuals with both hypertension and NAFLD remains unclear. This nationwide cohort study examined the independent and joint associations of PA and fatty liver burden with mortality in adults with hypertension. We analyzed 139,015 individuals aged ≥ 20 years who participated in the Korean National Health Insurance Service health screening program between 2009 and 2012 and were followed through 2021. Fatty liver burden was assessed using the Fatty Liver Index (FLI) and categorized as < 30, 30-59, or ≥ 60. PA levels were self-reported and classified as < 500, 500-999, and ≥ 1000 MET-min/week. Over a median follow-up of 9.1 years, 12,281 deaths occurred, including 2013 from cardiovascular causes. Higher FLI (≥ 60) was associated with significantly increased all-cause (HR 1.35, 95% CI 1.26-1.44) and cardiovascular mortality (HR 1.32, 95% CI 1.12-1.56). In contrast, higher PA (≥ 1000 MET-min/week) was consistently associated with lower mortality across all FLI categories, with the strongest benefit among those with FLI < 30 (HR 0.51 for all-cause mortality and 0.49 for CVD mortality). Importantly, high PA levels remained protective even in individuals with severe fatty liver burden. These findings suggest that regular PA substantially reduces mortality risk in adults with hypertension, regardless of underlying fatty liver severity. PA promotion should be considered an essential strategy in managing hypertension and related metabolic dysfunction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.